Observational studyTargeted oncology2022

Real-World Outcomes Among Crizotinib-Treated Patients with ROS1-Positive Advanced Non-Small-Cell Lung Cancer: A Community Oncology-Based Observational Study.

David Waterhouse et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.